Research at OnkPat
OnkPat consists of more than 30 research groups
Study shows how digital and molecular data can be integrated and used to improve health
Study shows how digital and molecular data can be integrated and used to improve health
Analysing molecular characteristics and their variation during lifestyle changes, by combining digital tools, classical laboratory tests and new biomolecular measurements, could enable individualised prevention of disease. This is according to a new study from OnkPat and the University of Helsinki in Finland published in the journal Cell Systems. The researchers show what a proactive healthcare model could comprise and how it could help in maintaining good health.
Congratulations to all researchers at OnkPat who received grants from Cancerfonden
The researchers at OnkPat who received grants from Cancerfonden are: Åsa Carlsson Tedgren, Hanna Eriksson, Theodoros Foukakis, Anita Göndör, Hildur Helgadottir, Thomas Helleday, Rolf Lewensohn, Stig Linder, Andreas Lundqvist, Isabelle Magalhaes, Sten Nilsson, Laura Orellana, Katja Pokrovskaja Tamm, Alexander Valdman, Klas Wiman, Arne Östman, Hanna Dahlstrand, Lotta Hansson.
Towards proteomics-based cancer precision medicine in lung cancer
Towards proteomics-based cancer precision medicine in lung cancer
A study lead by Janne Lehtiö and Lukas Orre describing a comprehensive proteogenomics analysis of lung cancer was published in Nature Cancer. The analysis reveals six molecular subtypes of lung cancer related to prognosis, oncogenic drivers and tumor immune landscape. The study indicates a future value of lung cancer subtypes and clinical proteomics for treatment stratification and precision medicine.
Promoting individualized implementation of functional precision cancer medicine in acute myeloid leukemia
Promoting individualized implementation of functional precision cancer medicine in acute myeloid leukemia
Olli Kallioniemi’s group and collaborators have published an article in Cancer Discovery entitled ”Implementing a functional precision medicine tumor board for acute myeloid leukemia”. This has been a 10-year effort to set up and launch functional precision cancer medicine and a molecular/functional tumor board in leukemia.